| Full text | |
| Author(s): Show less - |
de Oliveira, Marcos Vinicius Sousa
;
de Barros, Pedro Macul Ferreira
;
de Mathis, Maria Alice
;
Boavista, Rodrigo
;
Chacon, Priscila
;
Echevarria, Marco Antonio Nocito
;
Ferrao, Ygor Arzeno
;
Vattimo, Edoardo Felippo de Queiroz
;
Lopes, Antonio Carlos
;
Torres, Albina Rodrigues
;
Diniz, Juliana Belo
;
Fontenelle, Leonardo F.
;
do Rosario, Maria Conceicao
;
Shavitt, Roseli Gedanke
;
Miguel, Euripedes Constantino
;
da Silva, Renata de Melo Felipe
;
Costa, Daniel Lucas da Conceiao
Total Authors: 17
|
| Document type: | Journal article |
| Source: | Revista Brasileira de Psiquiatria; v. 45, n. 2, p. 16-pg., 2023-03-01. |
| Abstract | |
Objectives: To summarize evidence-based pharmacological treatments and provide guidance on clinical interventions for adult patients with obsessive-compulsive disorder (OCD).Methods: The American Psychiatric Association (APA) guidelines for the treatment of OCD (2013) were updated with a systematic review assessing the efficacy of pharmacological treatments for adult OCD, comprising monotherapy with selective serotonin reuptake inhibitors (SSRIs), clomipramine, serotonin and norepinephrine reuptake inhibitors (SNRIs), and augmentation strategies with clomipramine, antipsychotics, and glutamate-modulating agents. We searched for the literature published from 2013-2020 in five databases, considering the design of the study, primary outcome measures, types of publication, and language. Selected articles had their quality assessed with validated tools. Treatment recommendations were classified according to levels of evidence developed by the American College of Cardiology and the American Heart Association (ACC/AHA). Results: We examined 57 new studies to update the 2013 APA guidelines. High-quality evidence supports SSRIs for first-line pharmacological treatment of OCD. Moreover, augmentation of SSRIs with antipsychotics (risperidone, aripiprazole) is the most evidence-based pharmacological interven-tion for SSRI-resistant OCD. Conclusion: SSRIs, in the highest recommended or tolerable doses for 8-12 weeks, remain the first -line treatment for adult OCD. Optimal augmentation strategies for SSRI-resistant OCD include low doses of risperidone or aripiprazole. Pharmacological treatments considered ineffective or potentially harmful, such as monotherapy with antipsychotics or augmentation with ketamine, lamotrigine, or N-acetylcysteine, have also been detailed. (AU) | |
| FAPESP's process: | 14/50917-0 - INCT 2014: developmental psychiatry for children and adolescents |
| Grantee: | Eurípedes Constantino Miguel Filho |
| Support Opportunities: | Research Projects - Thematic Grants |